['knee osteoarthritis', 'blood clot', 'transfusion related complication', 'blood loss']
['oral tranexamic acid', 'oral aminocaproic acid']

        Inclusion Criteria:

          1. Age over 18 years

          2. Total replacement of the primary knee due to primary Osteoarthrosis

          3. Two-compartment prosthesis

          4. Unilateral procedure

          5. Cemented prosthesis

          6. Desire to participate voluntarily in the study and signature of informed consent

          7. Pre-operative assessment with result between ASA I, ASA II or ASA III performed and
             annexed in the clinical file either by the Department of Internal Medicine, Cardiology
             or Anesthesiology of our hospital.

          8. Possibility for oral administration of the drug.

        Exclusion Criteria:

          1. History of thrombotic or embolic event in the last 6 months

          2. Clinical history of coagulopathy

          3. Previous surgeries in the knee to intervene

          4. Patients who have received aspirin, platelet or cumarinic antiplatelet agents in the
             week prior to surgery or NSAIDs two days prior to surgery.

          5. History of myocardial infarction, arteriopathy or unstable angina in the 12 months
             prior to surgery.

          6. Those patients whose preoperative assessment corresponds to an ASA IV or the procedure
             is contraindicated in its preoperative assessment.

          7. Total revision knee replacement

          8. Total replacement of tumoral knee

          9. Total bilateral knee replacement

         10. Cognitive deficit

         11. Patients who meet the inclusion criteria but do not wish to participate in the study

         12. Patients with a diagnosis of Terminal Chronic Kidney Disease or with a serum
             creatinine higher than 1.47 mg / dl in the preoperative laboratories.

         13. Patients with inability to ingest the drug orally.

         14. Patients who are pregnant or breast-feeding or who are taking oral contraceptives.

         15. Seizure history

         16. Hypersensitivity to the active substance or to any of the excipients.
      